ProSavin® a gene therapy approach for the treatment of Parkinson's Disease: a Phase I Clinical Trial Update

被引：0

作者：

Palfi, Stephane ^{[1
,3
]}

Watts, Collin ^{[4
]}

Marc, Gurruchaga Jean ^{[3
]}

Peter, Buttery ^{[4
]}

Scott, Ralph ^{[2
]}

Sarah, Deeley ^{[2
]}

Helene, Lepetit ^{[3
]}

James, Miskin ^{[2
]}

Hiro, Iwamuro ^{[3
]}

Sonia, Lavisse ^{[1
]}

Aurelie, Kas ^{[1
]}

Laure, Ramelli Anne ^{[3
]}

Naoki, Tani ^{[3
]}

Gilles, Fenelon ^{[3
]}

Pierre, Brugie're ^{[3
]}

Stuart, Naylor ^{[2
]}

Philippe, Hantraye ^{[1
]}

Philippe, Remy ^{[1
,3
]}

Roger, Barker ^{[4
]}

Kyriacos, Mitrophanous ^{[2
]}

机构：

[1] CEA I2BM MirCen, Fontenay Aux Roses, France

[2] Oxford Biomed Ltd, Oxford, England

[3] Hop Henri Mondor, APHP, F-94010 Creteil, France

[4] Cambridge Ctr Brain Repair, Cambridge, England

来源：

HUMAN GENE THERAPY | 2012年 / 23卷 / 10期

关键词：

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

引用

页码：A61 / A61

页数：1

共 50 条

[21] Gene therapy for Parkinson's disease set to enter phase I trials
Butcher, J
LANCET NEUROLOGY, 2002, 1 (08): : 462 - 462
[22] Triple-gene therapy in Parkinson disease (ProSavin): Toward a putaminal dopamine factory?
Anheim, M.
REVUE NEUROLOGIQUE, 2014, 170 (02) : 89 - 90
[23] Nonclinical supporting studies for a first in man clinical trial using direct administration of a lentiviral vector (ProSavin®) for the treatment of Parkinson's disease
Miskin, James
Day, Debbie
Ferrige, Georgina
Loader, Julie
Angell-Manning, Diana
Esapa, Margaret
Mitrophanous, Kyriacos
HUMAN GENE THERAPY, 2008, 19 (10) : 1166 - 1166
[24] Gene therapy trial for Parkinson's disease begins
Oransky, I
LANCET, 2003, 362 (9385): : 712 - 712
[25] Development of a phase I clinical trial of gene therapy for chronic granulomatous disease
Malech, HL
Sekhsaria, S
WhitingTheobald, N
Linton, GF
Vowells, SJ
Li, F
Miller, JA
Holland, SM
Leitman, SF
Carter, CS
Read, EJ
Butz, R
Wannebo, C
Fleisher, TA
Deans, RJ
Spratt, SK
Maack, CA
Rokovich, JA
Cohen, LK
Maples, PB
Gallin, JI
BLOOD, 1995, 86 (10) : 1167 - 1167
[26] Early results from a clinical trial of AADC gene therapy for Parkinson's disease
Eberling, JL
Bankiewicz, KS
McGuire, D
Aminoff, M
Christine, C
Starr, P
Larson, P
Jagust, WJ
NEUROLOGY, 2006, 66 (05) : 276 - 277
[27] Improvements in Clinical and Radiographic Outcomes in a Phase I Study of AAV-GAD Gene Therapy for Parkinson's Disease
Kaplitt, Michael G.
Eidelberg, David
Feigin, Andrew
Fitzimmons, Helen
Lawlor, Patricia
Strybing, Kristin
Cox, Marie
Tang, Chris
Bland, Ross
During, Matthew J.
MOLECULAR THERAPY, 2006, 13 : S280 - S281
[28] Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial
Palfi, Stephane
Gurruchaga, Jean Marc
Ralph, G. Scott
Lepetit, Helene
Lavisse, Sonia
Buttery, Philip C.
Watts, Colin
Miskin, James
Kelleher, Michelle
Deeley, Sarah
Iwamuro, Hirokazu
Lefaucheur, Jean Pascal
Thiriez, Claire
Fenelon, Gilles
Lucas, Cherry
Brugieres, Pierre
Gabriel, Inanna
Abhay, Kou
Drouot, Xavier
Tani, Naoki
Kas, Aurelie
Ghaleh, Bijan
Le Corvoisier, Philippe
Dolphin, Patrice
Breen, David P.
Mason, Sarah
Guzman, Natalie Valle
Mazarakis, Nicholas D.
Radcliffe, Pippa A.
Harrop, Richard
Kingsman, Susan M.
Rascol, Olivier
Naylor, Stuart
Barker, Roger A.
Hantraye, Philippe
Remy, Philippe
Cesaro, Pierre
Mitrophanous, Kyriacos A.
LANCET, 2014, 383 (9923): : 1138 - 1146
[29] An update on the treatment of Parkinson's disease
Jankovic, Joseph
MOUNT SINAI JOURNAL OF MEDICINE, 2006, 73 (04): : 682 - 689
[30] Gene therapy for Parkinson disease shows promise in phase II trial
Katie Kingwell
Nature Reviews Neurology, 2011, 7 (5) : 241 - 241

← 1 2 3 4 5 →